Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicySelectHealth Actimmune Coverage & Prior Auth | Ope…
    Ask Trek AI about this page
    CurrentSelectHealthPolicy N/A

    Actimmune (interferon gamma-1b) — Coverage Criteria

    Customize your policy alerts

    Sign up for all SelectHealth policy alerts

    Know when SelectHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Criteria governing prior authorization and coverage for Actimmune (interferon gamma-1b) for SelectHealth members, including required diagnoses and exclusions. Affects providers requesting coverage under the payer's medical policy.

    Policy Summary
    PayerSelectHealth
    PolicyActimmune (interferon gamma-1b) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document a qualifying diagnosis (chronic granulomatous disease or severe malignant osteopetrosis) to support coverage.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    All FDA-Approved IndicationsPA scope
    Plan YearCoverage duration
    Hypersensitivity exclusionExclusion
    2Required diagnoses
    2

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Distinct indication blocks

    Coverage Criteria and Clinical Requirements

    Initial Coverage Criteria

    Covered when ALL of the following are met

    FDA indication: Actimmune prescribed for an FDA-approved indication.

    PA indication: All FDA-Approved Indications (chunk 1)

    Required diagnosis: Member has diagnosis of chronic granulomatous disease OR severe malignant osteopetrosis.

    Required medical information lists these two diagnoses (chunk 4)

    No exclusion: No documented hypersensitivity to Actimmune or E. coli derived products.

    Exclusion criterion (chunk 3)

    Coverage duration: Plan Year.

    chunk 7

    Alecensa (initial/maintenance)

    Alecensa is covered when ALL of the following are met

    Medication: Requested medication is Alecensa.

    Medication listed (chunk 22)

    PA indicator: Prior authorization indicator: All FDA‑Approved Indications.

    PA indicator (chunk 45)

    Required medical information: Diagnosis of non‑small cell lung cancer (NSCLC) with tumors that are ALK‑positive.

    Required medical information (chunk 26)

    Prerequisite therapy required and documented (per policy).

    Prerequisite therapy required flag (chunk 21)

    Radicava ORS (initial/maintenance)

    Radicava ORS is covered when ALL of the following are met

    Medication: Requested medication is Radicava ORS or Radicava ORS Starter Kit.

    Medication listed (chunk 33)

    PA indicator: Prior authorization indicator: All FDA‑Approved Indications.

    PA indicator (chunk 45)

    Required medical information: Diagnosis of amyotrophic lateral sclerosis (ALS) as defined by the revised El Escorial criteria.

    Required medical information (chunk 37)

    Coverage duration: Plan Year.

    chunk 40

    ALS (ALUNBRIG) — Initial/ongoing coverage

    Covered when ALL of the following are met

    Diagnosis of amyotrophic lateral sclerosis (ALS) as defined by the revised El Escorial criteria.

    Required medical information (chunk 37)

    Requested medication is ALUNBRIG.

    Medication listed (chunk 44)

    PA indicator: Prior authorization indicator: All FDA‑Approved Indications.

    chunk 45

    Coverage duration: Plan Year.

    chunk 40

    Metastatic ALK-positive NSCLC — ALUNBRIG or relevant agent

    Covered when ALL of the following are met

    Diagnosis of metastatic non‑small cell lung cancer (NSCLC) with tumors that are ALK‑positive.

    Required medical information (chunk 48)

    Prior therapy status: Patient has failed, is intolerant of, or has a contraindication to Alecensa.

    Required medical information includes prior Alecensa failure/intolerance/contraindication (chunk 48)

    Prerequisite therapy required (documented per policy).

    Prerequisite therapy required flag (chunk 21)

    Coverage duration: Plan Year.

    chunk 51

    PA indicator:

    Psychiatric/neurologic medication group

    Covered when ALL of the following are met

    Medication list: Requested medication is one of the listed psychiatric/neurologic products (e.g., CAPLYTA, COBENFY, FANAPT, LYBALVI, OPIPZA, VERSACLOZ, VRAYLAR strengths, etc.).

    Medication list (chunk 55)

    Prerequisite therapy required (documented).

    Prerequisite therapy required flag (chunk 54)

    Prior trial documentation: Document prior trial(s) specifying agent(s) tried and indication.

    Required prior trials guidance (chunk 59)

    Coverage duration: Plan Year.

    chunk 62

    Antipsychotic products - Initial Authorization

    Covered when ALL of the following are met

    Prerequisite therapy

    • Prior trial requirement: Previous trial on at least ONE of: aripiprazole, clozapine, fluoxetine‑olanzapine, haloperidol, olanzapine, quetiapine, risperidone, ziprasidone.

      chunk 59

    • MDD/Schizophrenia specific: For Major Depressive Disorder (MDD) or Schizophrenia: previous trial on Rexulti (brexpiprazole) required.

      chunk 59

    PA indication: PA indicator: 1 - All FDA‑Approved Indications.

    chunk 45

    Coverage duration: Plan Year.

    JUXTAPID (lomitapide) - Initial and Reauthorization

    Covered when ALL of the following are met

    Prerequisite therapy required (documented).

    chunk 65

    Exclusion criteria absent: Patient does NOT have history of significant hepatic disease or alcohol abuse.

    Exclusion criteria (chunk 69)

    Lipid thresholds: Fasting LDL cholesterol > 500 mg/dL AND triglycerides < 300 mg/dL.LDL > 500 mg/dL AND triglycerides < 300 mg/dL

    chunk 70

    Genetic/family/xanthoma criteria: Meets genetic or family history and xanthoma criteria as specified (mutations in both alleles OR parental history of untreated total cholesterol >250 mg/dL) with xanthomas before age 10.

    Initial Therapy - AQNEURSA

    Covered when ALL of the following are met for AQNEURSA:

    Prior therapy failure: Patient has tried and failed at least 3 months of miglustat therapy with documented lack of improvement in disease progression (examples: horizontal saccadic eye movements, SARA scale, R4DNPCCSS).

    Required medical information (chunk 80)

    Weight: Patient weighs >= 15 kg.>= 15 kg

    chunk 80

    Genetic or biochemical confirmation: Diagnosis is genetically confirmed by DNA sequence analysis with mutations in both alleles of NPC1 or NPC2 OR if only one allele mutated, positive filipin staining OR elevated cholestane triol/oxysterols (>2x ULN).

    chunk 80

    Neurologic symptoms and ambulatory status:

    Reauthorization - AQNEURSA

    Reauthorization covered when the following are met:

    Clinical response: fSARA score has remained stable or improved compared with baseline.

    Reauthorization criteria (chunk 80)

    Coverage duration: Initial coverage 6 months; reauthorization up to Plan Year per policy.

    chunk 73

    Initial Therapy - ARCALYST

    ARCALYST is covered for FDA-approved indications when documentation supports one of the following diagnoses and exclusion criteria are absent:

    Indications: Diagnosis of cryopyrin‑associated periodic syndrome OR recurrent pericarditis OR deficiency of Interleukin‑1 Receptor Antagonist (DIRA).

    Required medical information (chunk 88)

    Exclusions: Combination use with a TNF‑inhibitor is excluded.

    Exclusion criterion (chunk 87)

    Coverage duration: 6 months (initial) and/or Plan Year as specified in entry.

    chunks 83,90

    Initial Therapy

    Covered when ALL of the following are met

    Diagnosis and extent: Diagnosis of moderate to severe atopic dermatitis with >= 10% body surface area involvement.>= 10 percent

    Required medical information (chunk 99)

    Prior therapy failures: Failure of two of the following: topical corticosteroid; topical calcineurin inhibitor; phototherapy; oral immunomodulator (azathioprine, cyclosporine, or mycophenolate); topical PDE‑4 (Eucrisa).2 therapies failed

    Required medical information (chunk 99)

    PA indicator: Prior authorization indicator: All FDA‑Approved Indications.

    chunk 95

    Reauthorization — Adbry

    For reauthorization of Adbry

    Dosing trial for patients <100kg: Patients <100 kg who achieved clear or almost clear skin must have tried every‑4‑week dosing.every 4 week dosing tried

    Reauthorization detail (chunk 99)

    PA indicator: Prior authorization indicator: All FDA‑Approved Indications.

    chunk 95

    Entrectinib-like medication (oncology) coverage criteria

    Covered when ALL of the following are met

    Diagnosis of locally advanced or metastatic ROS1‑positive NSCLC OR NTRK gene fusion‑positive solid tumor.

    Required medical information (chunk 110)

    Prerequisite therapy: Contraindication, intolerance, or documented failure of Rozlytrek (prerequisite therapy required).

    Prerequisite therapy required (chunk 116)

    Coverage duration: Plan Year.

    chunk 113

    AUSTEDO products coverage criteria

    Covered when ALL of the following are met

    Indication: Diagnosis of chorea associated with Huntington's disease OR diagnosis of tardive dyskinesia.

    Required medical information (chunk 121)

    Products: Applies to AUSTEDO, AUSTEDO XR, and AUSTEDO XR patient titration.

    Medication list (chunk 117)

    Coverage duration: Plan Year.

    chunk 124

    Initial Therapy — AVMAPKI FAKZYNJA

    Covered when ALL of the following are met

    Diagnosis of recurrent KRAS‑mutated, recurrent low‑grade serous ovarian cancer.

    Required medical information (chunk 132)

    Prior therapy including platinum‑based therapy documented.

    chunk 132

    Performance status: ECOG performance status of 0 or 1 documented.

    chunk 132

    Prior Mekinist: Patient has been treated with Mekinist or a documented medical rationale explains why Mekinist is inappropriate.

    chunk 132

    PA indicator and coverage duration:

    Initial Therapy — AYVAKIT

    Covered when ANY one of the following diagnoses is documented

    Covered diagnoses: Unresectable or metastatic GIST that is PDGFRA exon 18 mutation‑positive (including D842V) OR Advanced Systemic Mastocytosis (ASM, SM‑AHN, MCL) OR Indolent Systemic Mastocytosis.

    Required medical information (chunk 142)

    PA indicator: Prior authorization indicator: All FDA‑Approved Indications; Coverage duration: Plan Year.

    chunks 139,145

    Initial Therapy — Balversa

    Covered when ALL of the following are met

    Diagnosis of locally advanced or metastatic urothelial carcinoma.

    Required medical information (chunk 153)

    Genetic confirmation: Confirmed FGFR3 genetic alteration documented.

    chunk 153

    Prior systemic therapy: Progression on or after at least one line of prior systemic therapy documented.

    chunk 153

    PA indicator: Prior authorization indicator: All FDA‑Approved Indications; Coverage duration: Plan Year.

    chunk 150

    Initial Therapy — Rufinamide

    Covered when ALL of the following are met

    Prerequisite therapy required (documented).

    Prerequisite therapy flag (chunk 159)

    Medication: Requested medication is Rufinamide.

    Medication list (chunk 160)

    PA indicator: Prior authorization indicator: All FDA‑Approved Indications.

    chunk 161

    Seizure-related required medical information

    Covered when ALL of the following are met

    Seizure control prerequisite: Patient has inadequate seizure control despite treatment with at least ONE anti‑epileptic drug.at least 1 anti‑epileptic tried

    Required medical information (chunk 164)

    SLE / Lupus Nephritis prior authorization criteria

    Covered when ALL of the following are met

    Diagnosis of lupus nephritis or systemic lupus erythematosus documented.diagnosis documented

    Required medical information (chunk 175)

    Active disease: Patient has current active disease.clinical documentation of active disease

    chunk 175

    Prior therapy: Previous treatment with at least TWO of: corticosteroids, antimalarials, immunosuppressives.>=2 classes tried

    chunk 175

    Initial Therapy - Besremi

    Covered when ALL of the following are met

    Diagnosis of polycythemia vera.

    Required medical information (chunk 186)

    Prior therapy failure: Inadequate response or intolerance to hydroxyurea documented.

    chunk 186

    PA required: Prior authorization obtained for Besremi.

    Medication listing (chunk 182)

    Coverage duration: Initial coverage: 6 months; Reauthorization: Plan Year.

    chunk 189

    Initial Therapy - Bosulif

    Covered when ALL of the following are met

    Diagnosis of Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia (CML) documented.

    Required medical information (chunk 197)

    Prior therapy failure: Previous failure or intolerance to imatinib documented (as applicable to disease phase).

    chunk 197

    PA required: Prior authorization obtained for Bosulif.

    Medication listing (chunk 193)

    Initial Therapy

    Covered when ALL of the following are met

    Mutation requirement: Documented BRAF V600E or V600K mutation‑positive disease for the intended indication (melanoma, metastatic colorectal cancer V600E when planned with cetuximab, or metastatic NSCLC).

    Required medical information (chunk 208)

    Intended combination therapy: Intended combination partner agents specified in documentation (eg, encorafenib + binimetinib for melanoma; encorafenib + cetuximab for colorectal cancer).

    chunk 208

    PA indicator: Prior authorization indicator: All FDA‑Approved Indications.

    chunk 205

    Initial Therapy - Caplacizumab

    Covered when ALL of the following are met

    Diagnosis of acquired thrombotic thrombocytopenic purpura (aTTP).

    Required medical information (chunk 219)

    Initial therapy setting: Therapy was started inpatient in combination with plasma exchange.

    Required medical information (chunk 219)

    Coverage duration limits: Coverage duration not to exceed 3 months; maximum therapy duration 58 days following last day of plasma exchange.

    chunks 222,223

    PA indicator: Prior authorization indicator: All FDA‑Approved Indications.

    chunk 216

    CABOMETYX - Indication-specific criteria

    Covered when ALL of the following are met

    Indication-specific diagnoses: Diagnosis corresponding to one of the CABOMETYX indications: HCC with prior sorafenib; advanced RCC; differentiated thyroid cancer after VEGFR‑targeted therapy and RAI‑refractory/ineligible; previously treated pNET after everolimus or sunitinib; previously treated epNET.

    Required medical information (chunk 230)

    PA indicator and coverage duration: Prior authorization indicator: All FDA‑Approved Indications; Coverage duration: Plan Year.

    chunks 227,233

    Calquence (acalabrutinib) coverage criteria

    Covered when documentation meets the following required information:

    Calquence - previously treated MCL: Diagnosis of mantle cell lymphoma AND member has been previously treated with at least one prior therapy.

    Required medical information (chunk 241)

    Calquence - treatment‑naïve MCL: Diagnosis of mantle cell lymphoma AND member is treatment‑naïve AND is ineligible for autologous HSCT AND Calquence will be used in combination with bendamustine and rituximab.

    chunk 241

    Calquence - other indications: Diagnosis of chronic lymphocytic leukemia OR diagnosis of small lymphocytic lymphoma.

    chunk 241

    Caprelsa (vandetanib) coverage criteria

    Covered when documentation meets the following required information:

    Caprelsa coverage: Diagnosis of symptomatic or progressive medullary thyroid cancer that is unresectable locally advanced or metastatic.

    Required medical information (chunk 251)

    Carglumic acid (initial/continuation)

    Covered when ALL of the following are met for carglumic acid:

    Indication: Diagnosis of hyperammonemia due to N‑acetylglutamate synthase (NAGS) deficiency documented.

    Required medical information (chunk 262)

    PA indicator: Prior authorization indicator: All FDA‑Approved Indications.

    chunk 259

    Sapropterin dihydrochloride (initial/continuation)

    Covered when ALL of the following are met for sapropterin:

    Indication: Diagnosis of hyperphenylalaninemia due to BH4‑responsive phenylketonuria documented.

    Required medical information (chunk 262)

    PA indicator: Prior authorization indicator: All FDA‑Approved Indications.

    chunk 259

    CHOLBAM

    Covered when ALL of the following are met for CHOLBAM:

    PA indicator: Prior authorization indicator: All FDA‑Approved Indications.

    chunk 270

    Medication: Requested medication is CHOLBAM.

    Medication listing (chunk 269)

    Coverage denial will be triggered if there is a documented hypersensitivity to Actimmune or E. coli–derived products. Providers must confirm the member has no known hypersensitivity in the medical record before authorization is approved.

    For the medications included in this section, the policy does not list any specific exclusion criteria — entries are marked N/A for exclusions or off‑label use. Providers should still verify product‑specific contraindications in the patient’s chart.

    This segment explicitly indicates No exclusion criteria are specified (marked N/A). If patient‑level risks exist, document them; absent documented exclusions in the policy, standard clinical contraindications and manufacturer labeling apply.

    JUXTAPID authorization excludes patients with a history of significant hepatic disease or alcohol abuse. Such histories should be documented and will preclude coverage per the policy exclusion statement.

    Use of AQNEURSA in combination with Miplyffa is specifically excluded. Requests showing concomitant use of these agents will be denied.

    ARCALYST is not covered when used in combination with a TNF‑inhibitor. Combination therapy with a TNF inhibitor is an explicit exclusion and may trigger denial.

    Concurrent use of the listed agents with another biologic (examples provided: Dupixent, Xolair, Humira, Entyvio, Otezla) is an exclusion. Documentation of combination biologic therapy will result in noncoverage.

    The document indicates no off‑label uses are listed (N/A) for the medications in these sections. Coverage decisions therefore apply only to FDA‑approved indications as detailed in each entry.

    Across these sections the policy records no additional exclusion criteria (N/A). Where exclusions are not specified, apply the stated coverage criteria and standard clinical contraindications.

    Named Medications, Formulations and Key Clinical Thresholds

    Named medicationsNDC | mixed
    AdbryMedication listed (brand name) — Adbry
    CibinqoMedication listed (brand name) — Cibinqo
    Named medicationsNDC | mixed
    AugtyroMedication listed (brand name) — Augtyro
    Medication formulationsNDC | HCPCS (formulation strings provided)
    BENLYSTA 200 MG/ML SOLN A-INJListed medication formulation
    BENLYSTA 200 MG/ML SOLN PRSYRListed medication formulation
    LDL / triglyceride thresholds for JUXTAPID
    LDL thresholdFasting LDL cholesterol > 500 mg/dL
    Triglyceride thresholdTriglycerides < 300 mg/dL
    Combined requirementBoth LDL > 500 mg/dL AND triglycerides < 300 mg/dL must be met
    Weight requirement
    Weight requirement>= 15 kg
    ContextRequired as part of AQNEURSA initial authorization clinical measures

    Prior Authorization, Documentation and Denial Triggers

    Prior Authorization

    Actimmune — Prior authorization required

    Prior authorization is required for Actimmune; coverage is limited to all FDA‑approved indications and authorization is granted for a plan year.

    Prior Authorization

    Alecensa — Prior authorization

    Prior authorization is required for Alecensa; the PA indicator applies to all FDA‑approved indications.

    Prior Authorization

    Radicava ORS — Prior authorization

    Prior authorization is required for Radicava ORS and the Radicava ORS Starter Kit; the PA indicator applies to all FDA‑approved indications.

    Background and Scope

    Actimmune (interferon gamma‑1b) is covered only for FDA‑approved indications. Per the policy, prior authorization is required and authorized coverage is issued for a Plan Year. Required documentation must include a diagnosis of either chronic granulomatous disease or severe malignant osteopetrosis, and the record must confirm absence of hypersensitivity to Actimmune or E. coli–derived products.

    Definitions and Key Terms

    Chronic granulomatous disease — definition (Actimmune authorized diagnosis)
    DefinitionChronic granulomatous disease: an inherited immunodeficiency resulting in recurrent infections
    Policy roleListed as an authorized diagnosis for Actimmune coverage (one of the required diagnoses)
    DocumentationDiagnosis must be included in required medical information for prior authorization
    Severe malignant osteopetrosis — definition (Actimmune authorized diagnosis)
    DefinitionSevere malignant osteopetrosis: a severe bone disorder
    Policy roleListed as an authorized diagnosis for Actimmune coverage (alternate required diagnosis)
    Policy Summary
    PayerSelectHealth
    PolicyActimmune (interferon gamma-1b) — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and document a qualifying diagnosis (chronic granulomatous disease or severe malignant osteopetrosis) to support coverage.
    SourceLink
    On This Page
    Coverage Criteria and Clinical RequirementsNamed Medications, Formulations and Key Clinical ThresholdsPrior Authorization, Documentation and Denial TriggersBackground and ScopeDefinitions and Key Terms
    Coverage duration: Plan Year.

    chunk 51

    Prior authorization indicator: All FDA‑Approved Indications.

    chunk 45

    chunk 62

    chunk 70

    Prior statin trial or intolerance: Failed or currently taking at least ONE statin (atorvastatin, rosuvastatin, simvastatin) OR has documented statin intolerance.

    chunk 70

    Prior PCSK9 inhibitor trial: Prior trial of Repatha OR Praluent required.

    chunk 70

    Coverage durations: Initial coverage: 6 months; Reauthorization: Plan Year.

    chunk 73

    Patient presents with at least one neurological symptom (eg, hearing loss, vertical supranuclear gaze palsy, ataxia, dementia, dystonia, seizures, dysarthria, dysphagia) AND is able to walk independently or with assistance.

    chunk 80

    Functional severity: SARA score >=7 and <=34 AND one of: (A) Gait subtest within 2-7 (0-8 range) OR (B) 9‑Hole Peg Test Dominant Hand (HPT‑D) time >=20 and <=150 seconds.SARA 7-34; HPT-D 20-150s

    chunk 80

    Exclusions: Use in combination with Miplyffa is excluded.

    chunk 79

    Prescriber restriction: Neurologist.

    chunk 82

    Coverage duration: Initial coverage: 6 months; Reauthorization per policy.Initial 6 mo; Reauth Plan Year

    chunk 73

    PA indicator: All FDA‑Approved Indications; Coverage duration: Initial 6 months (reauthorization requires documentation of no disease progression per RECIST v1.1).

    chunks 129,135,132

    Concomitant therapy:
    Will continue concomitant standard treatment with at least ONE of: corticosteroids, antimalarials, immunosuppressives.
    >=1 class concurrently

    chunk 175

    Prerequisite therapy required (flag present).

    chunk 181

    Documentation note
    Weight must be recorded in required medical information submitted with request
    SARA score threshold for AQNEURSA
    SARA score range>= 7 and <= 34 (out of 40)
    Associated functional requirementMust also meet gait subtest range (2–7 of 0–8) OR HPT-D time 20–150s
    UsePart of AQNEURSA eligibility and reauthorization assessment
    HPT-D time threshold for AQNEURSA
    HPT-D time range>= 20 and <= 150 seconds
    Test name9‑Hole Peg Test, Dominant Hand (HPT-D) — SCAFI subtest
    RoleOne of the functional criteria required alongside SARA for AQNEURSA eligibility
    Cholestane triol/oxysterols threshold
    Cholestane triol / oxysterols threshold> 2x upper limit of normal
    ContextAcceptable when only one NPC1/NPC2 allele mutation is identified (supports diagnosis)
    DocumentationReported as part of genetic/biochemical confirmation in AQNEURSA required information
    Body surface area threshold for atopic dermatitis
    Body surface area threshold>= 10 percent BSA
    ContextRequired for diagnosis of moderate to severe atopic dermatitis for Adbry/Cibinqo authorization
    DocumentationBSA involvement must be included in required medical information
    Adbry reauthorization dosing trial requirement
    Reauthorization dosing trialFor patients <100 kg who achieved clear or almost clear skin, every-4-week dosing must have been tried
    Applies toAdbry reauthorization only
    DocumentationClinical notes should document trial of every-4-week dosing prior to reauthorization approval
    RECIST v1.1 progression threshold
    RECIST v1.1 progression definition>= 20% increase in the sum of the diameters of target lesions
    Use caseRequired for AVMAPKI FAKZYNJA reauthorization to document absence of disease progression
    ReferenceProgression per RECIST v1.1 as specified in required medical information
    Prior Authorization

    Listed medications — Prior authorization required

    Prior authorization is required for the listed drugs in this section; ALUNBRIG is included with PA scope of all FDA‑approved indications.

    Prior Authorization

    Antipsychotic products — PA required

    Prior authorization is required for the listed antipsychotic products and prerequisite therapy is required as specified in the policy.

    Prior Authorization

    JUXTAPID — Prior authorization

    Prior authorization is required for JUXTAPID products; prerequisite therapy is required and specific clinical thresholds must be met.

    Prior Authorization

    AQNEURSA / ARCALYST — PA required

    Prior authorization is required for AQNEURSA and ARCALYST per the listed criteria in the policy.

    Prior Authorization

    PA applies to FDA‑approved indications

    Prior authorization applies to the listed medications for all FDA‑approved indications when the PA indicator is marked.

    Prior Authorization

    Adbry, Cibinqo, Augtyro — PA required

    Prior authorization is required for Adbry, Cibinqo, and Augtyro as listed in this section.

    Prior Authorization

    PA required for FDA‑approved indications

    Prior authorization applies to the listed medication(s) for all FDA‑approved indications when so indicated in the policy.

    Prior Authorization

    AVMAPKI FAKZYNJA — PA required

    Prior authorization is required for AVMAPKI FAKZYNJA for all FDA‑approved indications.

    Prior Authorization

    AYVAKIT — PA required

    Prior authorization is required for AYVAKIT for all FDA‑approved indications.

    Prior Authorization

    Listed medications — PA required for FDA indications

    Prior authorization is required for the listed medications in this segment and applies to all FDA‑approved indications as noted.

    Prior Authorization

    Benlysta — Prior authorization required

    Prior authorization is required for Benlysta products listed; PA covers all FDA‑approved indications and is granted for a plan year.

    Prior Authorization

    Besremi / Bosulif (Part B) — PA required

    Prior authorization is required for Besremi and Bosulif under Part B; prerequisite therapy is required for both agents per policy.

    Prior Authorization

    Listed medications — Prior authorization required

    Prior authorization is required for the listed medications and applies to all FDA‑approved indications noted for each drug.

    Prior Authorization

    Listed medications — PA for FDA indications

    Prior authorization is required for the listed medications for all FDA‑approved indications as indicated in the policy.

    Prior Authorization

    PA required — All FDA‑Approved Indications

    Prior authorization is required for the listed medications for all FDA‑approved indications (PA indicator = All FDA‑Approved Indications).

    Prior Authorization

    PA required for FDA‑approved indications (general)

    Prior authorization applies for all FDA‑approved indications for the listed medications in this section when indicated.

    Step Therapy

    Prerequisite therapy — Not required (N/A)

    No prerequisite therapy is required for the entries where 'N/A' is specified.

    Step Therapy

    Alecensa — Prerequisite therapy required

    Alecensa requires prerequisite therapy (PREREQUISITE THERAPY REQUIRED = YES) and documentation of prior therapy must be provided.

    Step Therapy

    Prerequisite therapy required — General

    Prerequisite therapy is required for the medication blocks where the policy indicates 'YES' for prerequisite therapy.

    Step Therapy

    Antipsychotic step therapy — Prior trial required

    For antipsychotic products, a trial of at least one listed antipsychotic is required prior to approval.

    • Previous trial must be on at least one of: aripiprazole, clozapine, fluoxetine‑olanzapine, haloperidol, olanzapine, quetiapine, risperidone, or ziprasidone.
    • For MDD or schizophrenia, a prior trial of Rexulti is required.
    Step Therapy

    JUXTAPID — Step therapy requirements

    For JUXTAPID, prior trial or intolerance to statin therapy plus a prior trial of a PCSK9 inhibitor (Repatha or Praluent) is required before approval.

    • Fasting LDL > 500 mg/dL AND triglycerides < 300 mg/dL must be documented.
    • Documented trial of at least one statin (atorvastatin, rosuvastatin, simvastatin) or documented statin intolerance.
    • Prior trial of Repatha OR Praluent is required.
    Step Therapy

    AQNEURSA — Step therapy (miglustat required)

    For AQNEURSA, the patient must have tried and failed at least 3 months of miglustat therapy prior to approval.

    • Provide evidence of lack of improvement after >=3 months of miglustat (examples: horizontal saccadic eye movements, SARA scale).
    • Use in combination with Miplyffa is excluded.
    Step Therapy

    Atopic dermatitis — Required prior therapy failures

    Coverage for atopic dermatitis agents requires prior failure of two specified therapies before approval.

    • Failure of two of: topical corticosteroid; topical calcineurin inhibitor; phototherapy; oral immunomodulator (azathioprine, cyclosporine, mycophenolate); topical PDE‑4 (Eucrisa).
    Step Therapy

    Entrectinib — Prerequisite therapy required

    Entrectinib requests must include contraindication, intolerance, or failure of Rozlytrek (prerequisite therapy required).

    Step Therapy

    AVMAPKI FAKZYNJA — Step therapy note

    AVMAPKI FAKZYNJA notes no general prerequisite but requires documentation of prior platinum‑based therapy and prior Mekinist treatment or rationale per the policy.

    • Reauthorization requires documentation showing no disease progression per RECIST v1.1.
    Step Therapy

    Rufinamide — Prerequisite therapy required

    Rufinamide requires prerequisite therapy as indicated by the policy prior to authorization.

    Step Therapy

    SLE / Lupus Nephritis — Prerequisite and concomitant therapy

    For SLE/lupus nephritis, the patient must have prior treatment with at least two specified agents and continue concomitant standard therapy with at least one of those classes.

    • Prior treatments must include at least two of: corticosteroids, antimalarials, immunosuppressives.
    • Concomitant continuation of at least one of those classes is required.
    Step Therapy

    Besremi — Step therapy prerequisites

    Besremi reauthorization and initial use require documentation showing inadequate response or intolerance to hydroxyurea (step therapy prerequisite).

    • Diagnosis of polycythemia vera and documentation of inadequate response or intolerance to hydroxyurea are required.
    Step Therapy

    BRAFTOVI / MEKTOVI — Prerequisite therapy

    BRAFTOVI/MEKTOVI group requires prerequisite therapy as specified in the policy.

    Step Therapy

    CABOMETYX — Prerequisite/step therapy

    For some CABOMETYX indications, prior specific therapies are required (e.g., prior sorafenib for HCC; prior VEGFR‑targeted therapy for DTC; failed everolimus or sunitinib for pNET).

    Step Therapy

    Prerequisite therapy — General requirement

    Prerequisite therapy is required where the policy indicates 'YES' for prerequisite therapy.

    Step Therapy

    No prerequisite therapy required

    No prerequisite or step therapy is required for the medications where the policy explicitly lists 'N/A' for prerequisite therapy.

    Documentation Required

    Actimmune — Required diagnosis documentation

    Documentation must include a diagnosis of chronic granulomatous disease OR severe malignant osteopetrosis for Actimmune requests.

    Documentation Required

    Alecensa — Required documentation (ALK‑positive NSCLC)

    Alecensa requests must include documentation of NSCLC that is ALK‑positive (tumors are ALK‑positive).

    Documentation Required

    Radicava ORS — Required documentation (ALS)

    Radicava ORS requests must include documentation of amyotrophic lateral sclerosis (ALS) as defined by the revised El Escorial criteria.

    Documentation Required

    ALS — Documentation per revised El Escorial criteria

    Required medical information for ALS must include documentation that the diagnosis meets the revised El Escorial criteria.

    Documentation Required

    ALK+ NSCLC — Required documentation

    For ALK‑positive NSCLC, documentation must show metastatic NSCLC with ALK‑positive tumors and that the patient has failed, is intolerant of, or has a contraindication to Alecensa where applicable.

    Documentation Required

    Antipsychotic group — Prior trial documentation

    Documentation of prior psychotropic medication trials must specify agents tried and the indication; for MDD or schizophrenia include evidence of a prior trial of Rexulti.

    Documentation Required

    JUXTAPID — Required medical information

    For JUXTAPID, required documentation includes fasting LDL > 500 mg/dL and triglycerides < 300 mg/dL, genetic testing or family history/xanthoma documentation as listed, documentation of statin trial or intolerance, and prior trial of Repatha or Praluent.

    Documentation Required

    AQNEURSA — Required documentation

    AQNEURSA documentation must show trial and failure of at least 3 months of miglustat with evidence of lack of improvement in disease progression.

    • Include neurologic symptom documentation, ambulatory status, weight (>=15 kg), SARA and functional test scores where applicable.
    • Provide genetic confirmation per policy or alternative biochemical evidence if one allele mutated.
    Documentation Required

    AQNEURSA — Genetic confirmation required

    AQNEURSA requests must include genetic confirmation by DNA sequence analysis showing mutations in both alleles of NPC1 or NPC2, or if only one allele mutated provide positive filipin staining or elevated cholestane triol/oxysterols (>2x ULN).

    Documentation Required

    AQNEURSA — Clinical measures to document

    AQNEURSA clinical measures documentation must include neurologic symptoms, ambulatory status, weight (>=15 kg), SARA score, and specified functional test results (e.g., HPT‑D).

    • SARA score must be >=7 and <=34.
    • HPT‑D time must be >=20 and <=150 seconds.
    Documentation Required

    ARCALYST — Required documentation

    ARCALYST documentation must support one of the covered diagnoses: cryopyrin‑associated periodic syndrome, recurrent pericarditis, or deficiency of IL‑1 receptor antagonist (DIRA).

    Documentation Required

    Atopic dermatitis — Required documentation

    Atopic dermatitis documentation must show diagnosis of moderate to severe disease with >=10% body surface area and failure of two specified prior therapies; for Adbry reauthorization, patients <100 kg who achieved clear or almost clear skin must have tried every‑4‑week dosing.

    Documentation Required

    AUGTYRO — Prerequisite therapy documentation

    AUGTYRO requests require prerequisite therapy (policy indicates 'YES'); details must be provided in the clinical documentation.

    Documentation Required

    Entrectinib — Required documentation

    Entrectinib requests must include diagnosis of locally advanced or metastatic ROS1‑positive NSCLC or NTRK gene fusion‑positive solid tumors and documentation of contraindication, intolerance, or failure of Rozlytrek.

    Documentation Required

    AUSTEDO — Required documentation

    AUSTEDO documentation must include diagnosis of chorea associated with Huntington's disease or diagnosis of tardive dyskinesia.

    Documentation Required

    AVMAPKI FAKZYNJA — Required documentation

    AVMAPKI FAKZYNJA documentation must include diagnosis of recurrent KRAS‑mutated low‑grade serous ovarian cancer, prior platinum‑based therapy, ECOG 0–1, prior Mekinist treatment or documented rationale, and for reauthorization documentation of no progression per RECIST v1.1.

    • RECIST v1.1 progression is defined as >=20% increase in sum of diameters of target lesions.
    Documentation Required

    AYVAKIT — Required documentation

    AYVAKIT documentation must include one of the covered diagnoses (PDGFRA exon 18 mutation–positive GIST including D842V, Advanced Systemic Mastocytosis subtypes, or Indolent Systemic Mastocytosis).

    Documentation Required

    Balversa — Required documentation

    Balversa documentation must include diagnosis of locally advanced or metastatic urothelial carcinoma, confirmation of FGFR3 genetic alteration, and evidence of progression on or after at least one line of prior systemic therapy.

    Documentation Required

    Rufinamide — Required documentation

    Rufinamide documentation must include evidence of prerequisite therapy as indicated by the policy for the seizure indication.

    Documentation Required

    SLE / Lupus Nephritis — Clinical documentation required

    For SLE/lupus nephritis, required clinical documentation must include diagnosis, current active disease status, prior treatments, and planned concomitant standard therapy.

    • Document prior treatments and plan to continue at least one concomitant standard therapy (corticosteroid, antimalarial, or immunosuppressive).
    Documentation Required

    Besremi — Required documentation

    Besremi initial requests must include diagnosis of polycythemia vera and documentation of inadequate response or intolerance to hydroxyurea.

    Documentation Required

    BRAF mutation — Diagnostic documentation required

    Documentation of a BRAF V600E or V600K mutation is required for encorafenib/binimetinib combinations and related indications.

    Documentation Required

    Caplacizumab — Required documentation

    Caplacizumab requests must document diagnosis of acquired thrombotic thrombocytopenic purpura (aTTP) and that therapy was started inpatient in combination with plasma exchange.

    Documentation Required

    CABOMETYX — Required documentation

    CABOMETYX documentation must include the specific diagnosis corresponding to the listed indications and supporting prior therapy history where specified.

    Documentation Required

    Calquence — Required documentation

    Calquence documentation must include diagnosis (mantle cell lymphoma, chronic lymphocytic leukemia, or small lymphocytic lymphoma) and HSCT eligibility/prior treatment details when applicable.

    Documentation Required

    Caprelsa — Required diagnostic documentation

    Caprelsa requests must document symptomatic or progressive medullary thyroid cancer that is unresectable locally advanced or metastatic.

    Documentation Required

    Carglumic acid / Sapropterin — Required documentation

    For carglumic acid and sapropterin, documentation must confirm the specific metabolic diagnoses (NAGS deficiency for carglumic acid; BH4‑responsive PKU for sapropterin).

    Denial Risk

    Actimmune — Hypersensitivity exclusion (denial risk)

    A documented hypersensitivity to Actimmune or E. coli‑derived products is an explicit exclusion and will trigger denial of coverage.

    Denial Risk

    Missing required diagnosis — Denial risk

    Requests that lack the required diagnosis (for example, ALK‑positive NSCLC for Alecensa or ALS per revised El Escorial criteria for Radicava ORS) may be denied.

    Denial Risk

    Alecensa — Prerequisite therapy not documented (denial risk)

    Failure to document prerequisite therapy where required for Alecensa may result in denial.

    Denial Risk

    ALS — Diagnosis documentation missing (denial risk)

    Lack of documentation confirming ALS per the revised El Escorial criteria may trigger denial for Radicava ORS or related ALS entries.

    Denial Risk

    ALK+ NSCLC — Missing prior therapy or diagnosis (denial risk)

    Failure to document metastatic ALK‑positive NSCLC or failure/intolerance/contraindication to Alecensa may trigger denial.

    Denial Risk

    Antipsychotic trials — Missing documentation (denial risk)

    Failure to document required prior antipsychotic trials (including agents listed or Rexulti for MDD/schizophrenia) may result in denial.

    Denial Risk

    JUXTAPID — Prerequisite failures (denial risk)

    For JUXTAPID, not meeting LDL/triglyceride thresholds, lacking genetic/family/xanthoma documentation, or lacking documented trials/intolerance to statins and PCSK9 inhibitor may trigger denial.

    • Required thresholds: untreated fasting LDL > 500 mg/dL AND triglycerides < 300 mg/dL.
    Denial Risk

    AQNEURSA — Combination with Miplyffa excluded

    Use of AQNEURSA in combination with Miplyffa is an exclusion and may trigger denial.

    Denial Risk

    ARCALYST — TNF‑inhibitor combination excluded

    Combination use of ARCALYST with a TNF‑inhibitor is excluded and may result in denial.

    Denial Risk

    Combination biologic use — Exclusion (denial risk)

    Use of specified medications in combination with another biologic (examples listed) is excluded and may trigger denial.

    • Examples: Dupixent, Xolair, Humira, Entyvio, Otezla.
    Denial Risk

    Entrectinib — Missing diagnosis/prior therapy (denial risk)

    Lack of required diagnosis or prior therapy documentation for Entrectinib (ROS1‑positive NSCLC or NTRK fusion tumors and Rozlytrek failure/intolerance) may trigger denial.

    Denial Risk

    AUSTEDO — Missing diagnosis (denial risk)

    Absence of a documented diagnosis of chorea due to Huntington's disease or tardive dyskinesia may trigger denial for AUSTEDO.

    Denial Risk

    AVMAPKI FAKZYNJA — Documentation triggers (denial risk)

    Lack of required documentation for AVMAPKI FAKZYNJA (diagnosis, prior platinum therapy, ECOG 0–1, Mekinist treatment/rationale, reauthorization RECIST evidence) may trigger denial.

    Denial Risk

    AYVAKIT — Missing required documentation (denial risk)

    Lack of required documentation for AYVAKIT (one of the specified diagnoses) may trigger denial.

    Denial Risk

    Balversa — FGFR3 confirmation required (denial risk)

    Absence of documented FGFR3 genetic alteration or lack of progression after prior systemic therapy may trigger denial for Balversa.

    Denial Risk

    Rufinamide — Missing prerequisite therapy (denial risk)

    If prerequisite therapy is not documented for Rufinamide, authorization may be denied.

    Denial Risk

    Seizure indication — Inadequate documentation (denial risk)

    For seizure indications, lack of documentation that the patient has inadequate seizure control despite at least one anti‑epileptic drug may trigger denial.

    Denial Risk

    Besremi / Bosulif — Missing clinical rationale (denial risk)

    Missing required clinical rationale (e.g., Besremi: polycythemia vera and inadequate response/intolerance to hydroxyurea; Bosulif: Ph+ CML and imatinib failure/intolerance) may trigger denial.

    Denial Risk

    BRAF mutation documentation missing (denial risk)

    Lack of documented BRAF V600E or V600K mutation for intended encorafenib/binimetinib or related uses may trigger denial.

    Denial Risk

    Caplacizumab — Missing prerequisite documentation (denial risk)

    Caplacizumab requests lacking documentation of aTTP diagnosis and inpatient initiation with plasma exchange may be denied.

    Denial Risk

    CABOMETYX — Missing prerequisite documentation (denial risk)

    For CABOMETYX, lack of required disease‑specific documentation (e.g., prior sorafenib for HCC; prior VEGFR therapy for DTC; failed everolimus/sunitinib for pNET) may trigger denial.

    Denial Risk

    Calquence — Insufficient history (denial risk)

    Insufficient diagnostic or treatment history for Calquence (e.g., mantle cell lymphoma prior therapy or HSCT eligibility) may trigger denial.

    Denial Risk

    Caprelsa — Insufficient diagnostic documentation (denial risk)

    Lack of required documentation demonstrating symptomatic or progressive medullary thyroid cancer that is unresectable locally advanced or metastatic may trigger denial for Caprelsa.

    Denial Risk

    Missing required medical information — General denial risk

    Requests missing required clinical information per the diagnosis‑specific required medical information sections may be denied.

    DocumentationDiagnosis must be provided in required medical information for prior authorization
    ALK-positive NSCLC — definition
    DefinitionALK-positive NSCLC: tumors are anaplastic lymphoma kinase (ALK)-positive
    Policy roleRequired diagnostic confirmation for Alecensa coverage
    DocumentationDiagnosis must be included in required medical information submitted with request
    ALS (per revised El Escorial criteria)
    DefinitionALS as defined by the revised El Escorial criteria
    Policy roleRequired diagnostic standard for Radicava ORS and related ALS coverage entries
    DocumentationConfirmation of ALS per revised El Escorial criteria must be included in required medical information
    ALS (per revised El Escorial criteria) — duplicate definition entry
    Definition (duplicate)Diagnosis of amyotrophic lateral sclerosis as defined by the revised El Escorial criteria
    NoteSame wording and requirement as other ALS definition entry; included for completeness
    DocumentationRequired in medical information for ALS-related drug requests
    ALK-positive metastatic NSCLC — definition
    DefinitionALK-positive metastatic NSCLC: metastatic NSCLC with tumors that are ALK-positive
    Policy roleRequired diagnosis for ALUNBRIG or relevant agent coverage when Alecensa cannot be used
    DocumentationRequest must document metastatic ALK-positive NSCLC and failure/intolerance/contraindication to Alecensa as applicable
    PA indication indicator — 'All FDA-Approved Indications' meaning
    MeaningPA indication indicator '1 - All FDA-Approved Indications' means prior authorization applies to all FDA-approved indications for the medication
    Policy impactUsed across multiple entries to indicate PA scope covers any FDA-approved use
    DocumentationWhen this indicator is present, required medical information must still be provided per indication-specific rules
    SARA score — definition and thresholds
    DefinitionSARA score: Scale for the Assessment and Rating of Ataxia
    Thresholds>= 7 and <= 34 required for AQNEURSA eligibility
    RoleUsed with gait subtest or HPT-D results as part of functional severity criteria
    HPT-D (9-Hole Peg Test Dominant Hand)
    DefinitionHPT-D: 9-Hole Peg Test, Dominant Hand (SCAFI subtest)
    Threshold>= 20 and <= 150 seconds required for AQNEURSA eligibility as one functional option
    ContextMeasured as part of the SCAFI battery included in AQNEURSA clinical criteria
    Moderate to severe atopic dermatitis — definition (>=10% BSA)
    DefinitionModerate to severe atopic dermatitis: involvement of >= 10% body surface area
    Policy roleRequired threshold for initial authorization of Adbry/Cibinqo
    DocumentationBSA must be documented in required medical information
    Failure of two therapies — definition
    DefinitionFailure of two therapies: inadequate response to two of the following - topical corticosteroid, topical calcineurin inhibitor, phototherapy, oral immunomodulator (azathioprine, cyclosporine, mycophenolate), or topical PDE-4 (Eucrisa)
    Policy roleRequired prior therapy failure definition for moderate to severe atopic dermatitis authorization
    DocumentationRecords must show trials and inadequate response to two qualifying therapies
    Entrectinib-like required medical information — definition
    DefinitionRequired medical information for Entrectinib-like requests: diagnosis of locally advanced or metastatic ROS1-positive NSCLC OR NTRK gene fusion-positive solid tumors and contraindication/intolerance/failure of Rozlytrek
    Policy rolePrerequisite therapy or failure of Rozlytrek must be documented
    DocumentationInclude diagnostic testing confirming ROS1 or NTRK fusion and prior therapy history
    AUSTEDO required medical information — definition
    DefinitionAUSTEDO required medical information: diagnosis of chorea associated with Huntington's disease OR diagnosis of tardive dyskinesia
    ProductsApplies to AUSTEDO formulations listed in policy
    DocumentationDiagnostic documentation must accompany PA request
    Disease progression (per RECIST v1.1)
    DefinitionDisease progression per RECIST v1.1: >= 20% increase in the sum of diameters of target lesions
    Policy roleUsed to determine reauthorization/no progression for AVMAPKI FAKZYNJA
    DocumentationRadiographic measurements must demonstrate changes per RECIST v1.1 criteria
    Advanced Systemic Mastocytosis (AdvSM)
    DefinitionAdvanced Systemic Mastocytosis (AdvSM) includes aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL)
    Policy roleListed as an indication for AYVAKIT when documented
    DocumentationSpecify subtype of systemic mastocytosis in required medical information
    FGFR3 genetic alteration — definition for Balversa
    DefinitionFGFR3 genetic alteration: a confirmed fibroblast growth factor receptor 3 genetic alteration
    Policy roleRequired for Balversa eligibility in urothelial carcinoma
    DocumentationGenetic testing confirming FGFR3 alteration must be submitted
    At least two of: corticosteroids, antimalarials, immunosuppressives
    DefinitionAt least two of: corticosteroids, antimalarials, immunosuppressives — prior treatments required for SLE/lupus nephritis
    Policy rolePatient must have previous treatment with at least two of these classes before authorization
    DocumentationProvide records of prior therapies and responses
    Continued use of at least one of: corticosteroids, antimalarials, immunosuppressives
    DefinitionContinued use of at least one of: corticosteroids, antimalarials, immunosuppressives — concomitant standard therapy requirement
    Policy roleRequired for ongoing coverage of SLE/lupus nephritis therapies
    DocumentationPlan for and documentation of continued concomitant therapy must be included
    treatment failure/intolerance definition
    DefinitionTreatment failure/intolerance: inadequate response or intolerance to prior therapy
    Policy roleUsed to establish eligibility where prior therapy failure or intolerance is a prerequisite (e.g., Besremi, Bosulif, Rufinamide)
    DocumentationClinical notes should document the nature of failure or intolerance to prior agents
    Ph+ CML definition
    DefinitionPh+ CML: Philadelphia chromosome–positive chronic myeloid leukemia
    Policy roleRequired diagnosis for Bosulif coverage entries
    DocumentationProvide phase of disease and prior therapy history including imatinib failure/intolerance where applicable
    BRAF V600 mutation-positive definition
    DefinitionBRAF V600 mutation-positive: BRAF V600E or V600K mutation-positive
    Policy roleRequired diagnostic mutation for encorafenib/binimetinib combination and related indications
    DocumentationMolecular testing demonstrating BRAF V600 mutation must be submitted
    Required Medical Information summary (caplacizumab / CABOMETYX context)
    SummaryRequired medical information must include diagnosis-specific documentation and prior-therapy history (e.g., caplacizumab: aTTP started inpatient with plasma exchange; CABOMETYX: indication-specific prior therapies such as prior sorafenib for HCC)
    UseApplies to caplacizumab and CABOMETYX entries among others
    DocumentationInclude inpatient/plasma exchange start for aTTP or prior systemic therapies for CABOMETYX indications
    HSCT ineligibility (Calquence context)
    HSCT ineligibility requirementWhen Calquence is used first-line for mantle cell lymphoma, documentation that the member is ineligible for autologous HSCT must be provided
    Policy roleApplies when Calquence is planned as treatment-naïve option combined with bendamustine and rituximab
    DocumentationProvide evaluation showing HSCT ineligibility and treatment plan including combination therapy
    Symptomatic or progressive medullary thyroid cancer definition
    DefinitionSymptomatic or progressive medullary thyroid cancer: disease causing symptoms or demonstrating radiographic/clinical progression and unresectable locally advanced or metastatic
    Policy roleRequired for Caprelsa authorization
    DocumentationProvide clinical/radiographic evidence of symptomatic or progressive unresectable/metastatic disease
    Hyperammonemia due to NAGS deficiency (carglumic acid)
    DefinitionHyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency
    Policy roleRequired diagnostic indication for carglumic acid prior authorization
    DocumentationConfirm elevated ammonia and NAGS deficiency in submitted medical information
    BH4-responsive phenylketonuria (sapropterin)
    DefinitionBH4-responsive phenylketonuria (PKU): hyperphenylalaninemia that responds to tetrahydrobiopterin (BH4)
    Policy roleRequired for sapropterin authorization
    DocumentationDocument BH4-responsiveness in diagnostic testing submitted with request